TRITON2: Rucaparib for metastatic castration-resistant prostate cancer

Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042

IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours

Blood first assay screening in patients with ALK positive NSCLC

CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma

INVICTUS: Assessing the safety and efficacy of ripretinib in patients with advanced gastrointestinal stromal tumours

Using PARP inhibitors to improve quality of life for patients with metastatic breast cancer

Holistic management of patients with ALK-positive NSCLC

Melanoma highlights from ESMO 2019

ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma